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A B S T R A C T
A total of 1561 pneumococcal isolates were collected in 1997–2001, mainly from patients with
community-acquired respiratory tract infections, and susceptibilities were tested by reference broth
microdilution against 29 antimicrobial agents. In general, 69.3% of strains were considered susceptible
(MIC £ 0.06 mg ⁄L) to penicillin. Resistance to penicillin (MIC ‡ 2 mg ⁄L) and cefotaxime
(MIC ‡ 4 mg ⁄L) was found in 11.9% and 0.4% of isolates, respectively. The fluoroquinolones
gatifloxacin (MIC90, 0.5 mg ⁄L) and levofloxacin (MIC90, 1 mg ⁄L) were active against > 99% of the
isolates tested. Among the other non-b-lactam drugs tested, the rank order of susceptibility was
chloramphenicol (95.6%) > clindamycin (94.5%) > azithromycin (88.5%) > clarithromycin (87.5%) >
tetracycline (79.5%) > trimethoprim + sulphamethoxazole (60.5%). The penicillin-non-susceptible iso-
lates presented higher rates of resistance to other antimicrobial agents. The rank order of penicillin
resistance rates among the seven participating countries was Mexico (25.0%) > Uruguay
(19.2%) > Chile (18.3%) > Colombia ¼ Argentina (9.9%) > Brazil (3.9%) > Venezuela (2.8%). The
regional rate of penicillin resistance did not vary significantly over the years studied (p 0.339).
Screening for the ermB and mefA genes by multiplex rapid cycle PCR on 23 erythromycin-resistant
isolates collected during the year 2001 showed that 43.5% and 56.5%, respectively, were positive for
ermB and mefA. Overall, the results indicated that antimicrobial susceptibilities of Streptococcus
pneumoniae vary significantly among Latin American countries. Regional and local surveillance
programmes are necessary to guide empirical therapy of pneumococcal infection in Latin American
countries.
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I N T R O D U C T I O N
Streptococcus pneumoniae remains a major cause of
morbidity and mortality in humans. This pathogen
accounts for most cases of community-acquired
pneumonia and other respiratory infections. In
addition, it is a leading cause of meningitis,
particularly in adults, and acute otitis media in
children. During the past 30 years, pneumococci
have developed resistance to several antimicro-
bial agents, including penicillin, tetracycline,
trimethoprim + sulphamethoxazole, chloram-
phenicol, erythromycin and cephalosporins [1].
The emergence and worldwide dissemination
of penicillin resistance among S. pneumoniae
strains represents an important problem in the
treatment of respiratory tract infections [2,3].
Infections caused by penicillin-non-susceptible
strains may be treated intravenously with third-
generation cephalosporins. However, there are
very few options available to treat infections, espe-
cially meningitis, caused by strains resistant to
third-generation cephalosporins, since glycopep-
tides do not penetrate well into the central ner-
vous system. In addition, the fluoroquinolones,
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which remain very active against multiresistant
pneumococci, have not yet been approved for use
in children [1,4].
Since pneumococcal infections are usually trea-
ted empirically and the susceptibility patterns are
not predictable, surveillance programmes are
necessary to guide antimicrobial therapy. The
SENTRY Antimicrobial Surveillance Program was
established in 1997 to monitor antimicrobial
resistance patterns of nosocomial and commu-
nity-acquired infections via national and interna-
tional networks of sentinel medical centres. The
aim of this study was to evaluate and compare
antimicrobial resistance rates among S. pneumoni-
ae isolates from Latin American countries during
1997–2001.
M A T E R I A L S A N D M E T H O D S
Bacterial strains
In total, 1561 S. pneumoniae isolates collected consecutively by
the participating clinical microbiology laboratories from Janu-
ary 1997 to December 2001 were evaluated. Only isolates
judged to be the cause of defined community-acquired
respiratory infections were included in the study. Respiratory
tract specimens included high-quality sputum, tracheal aspir-
ate and bronchoalveolar lavage. Only specimens with high
numbers of macrophages and low numbers of epithelial cells
were accepted [5]. Strains isolated from the blood of patients
with community-acquired respiratory tract infections were
also included in the study.
Ten Latin American laboratories participated in the study
each year. The laboratories were in six countries (nine cities):
Sao Paulo, Rio de Janeiro, Florianopolis, Porto Alegre and
Brasilia, Brazil; Buenos Aires and San Isidro, Argentina;
Santiago (two centres), Chile; Medellin, Colombia; Mexico
City, Mexico; and Montevideo, Uruguay. In 1998, the Monte-
video centre was replaced by a centre in Caracas, Venezuela,
and in 1999, the Brazilian centre located in Rio de Janeiro was
replaced by a centre in Porto Alegre, which is also located in
the southern region of Brazil. In 2001, the centre located
in Medellin, Colombia was replaced by a centre located in
Brasilia, Brazil. The selection of centres was based on the
principle that they should be sentinels for their respective
geographical regions. All isolates were saved on agar slants
and sent to the monitoring centre for storage and further
characterisation by reference identification and susceptibility
testing methods. Erythromycin-resistant isolates collected dur-
ing the year 2001 were selected randomly and screened for the
ermB and mefA genes [6].
Species identification
The isolates were identified at the participating centre by the
routine methodology used at each laboratory. Upon receipt at
the monitoring laboratory, the isolates were subcultured on
blood agar to ensure viability and purity. Species identification
was confirmed or performed with the Vitek system (bio-
Me´rieux, Hazelwood, MO, USA) or API (bioMe´rieux) products
and standard reference methods [7]. Isolates were frozen at
) 70C until they were processed.
Susceptibility testing
Antimicrobial susceptibility testing of isolates was performed
by reference broth microdilution methods [8]. Antimicrobial
agents were obtained from their respective manufacturers.
Quality control was performed by testing Escherichia coli ATCC
25922, Staphylococcus aureus ATCC 29213, Pseudomonas aerugi-
nosa ATCC 27853, S. pneumoniae ATCC 49619, and Enterococcus
faecalis ATCC 29212. Interpretive criteria for each antimicrobial
agent tested were as published previously [9]. Rates of
susceptibility to cefotaxime were calculated according to the
breakpoints for non-meningitis isolates (£ 1 mg ⁄L) [9].
Molecular analysis
Screening for ermB and mefA was performed by multiplex
rapid cycle PCR as described by Farrell et al. [6]. Molecular
characterisation of the quinolone resistance-determining re-
gion was performed by PCR amplification of the gyrA, gyrB,
parC and parE genes, followed by sequencing of the amplicons
as described previously [10].
Statistical analysis
Data were analysed with SPSS for Windows Release 10.0.5–
Standard Version (SPSS Inc., Chicago, IL, USA). Fisher’s exact
test and v2 for trend were used to compare proportional
differences for penicillin-resistant S. pneumoniae isolates among
periods and regions. Differences were considered statistically
significant at a p value of < 0.05.
R E S U L T S
The isolates were collected either from the respir-
atory tract (77%) or blood (23%), with 33% of
patients hospitalised at the time the specimen was
collected. Patient age data were not available for c.
50% of the cases. However, where ages were
known, the distribution was as follows: £ 5 years,
27.7%; 6–20 years, 8.5%; 21–40 years, 15.8%;
41–64 years, 24.1%; and ‡ 65 years, 24%.
The in-vitro activities of selected antimicrobial
agents tested against the S. pneumoniae isolates are
summarised in Table 1. Among 1561 strains
evaluated, 69.3% were susceptible to penicillin
(MIC £ 0.06 mg ⁄L), 18.8% were intermediate
(MIC of 0.12–1 mg ⁄L), and 11.9% had high-level
resistance (MIC ‡ 2 mg ⁄L). An analysis of peni-
cillin resistance rates (MIC ‡ 2 mg ⁄L) according
to age group showed that the highest rate was
detected in children aged £ 5 years (15.6%), fol-
lowed by the 41–60-year group (15.5%), the
‡ 65-year group (11.3%), the 21–40-year group
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(7.3%) and the 6–20-year group (3.4%). The
penicillin MIC distribution among the isolates
from patients whose ages were not known was
very similar to that of the entire collection (data
not shown).
Based on susceptibility breakpoints established
in 2003 for non-meningitis isolates [9], cefotaxime
resistance was found in only 0.4% of the total
isolates. Amoxycillin (MIC90, 1 mg ⁄L) was active
against 98.2% of isolates, while the fluoroquino-
lones gatifloxacin (MIC90, 0.5 mg ⁄L) and levofl-
oxacin (MIC90, 1 mg ⁄L) inhibited 99.8% of the
isolates at the susceptible breakpoints. Only three
fluoroquinolone-resistant isolates were identified
in the entire collection; these were isolated from
the lower respiratory tract of adults. Two of these
were isolated in Argentina in 1999 and the other
was isolated in Chile in 2001. All isolates had
levofloxacin MICs of > 32 mg ⁄L when tested by
Etest and a double mutation in the quinolone
resistance-determining region. All isolates had a
parC Ser79(r)Phe mutation, two isolates had an
additional gyrB A435(r)Ile mutation, and the third
isolate had an additional gyrA Ser83(r)Phe muta-
tion.
In contrast, susceptibility rates were low for
trimethoprim + sulphamethoxazole (60.5%), tet-
racycline (79.5%), and the cephalosporins cefpro-
zil, cefpodoxime and cefuroxime (84.1–84.5%).
Erythromycin and the newer macrolides (azith-
romycin and clarithromycin) demonstrated
Table 1. In-vitro antimicrobial sus-
ceptibilities of Streptococcus pneumo-
niae isolates from Latin American
hospitals participating in the SEN-
TRY Antimicrobial Surveillance Pro-
gram (1997–2001; 1561 strains)
Antimicrobial agent
Cumulative percentage inhibited at indicated concentration (mg ⁄L)a
£ 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32
Penicillin 60.7 69.3 77.1 82.3 85.1 88.1 95.6 99.6 > 99.9b – –
Amoxycillin – 74.9 80.7 83.7 85.6 90.8 98.2 99.6 > 99.9b – –
Cefuroximeb – 60.8 69.7 74.7 81.3 84.5 86.9 93.5 99.7b – –
Cefprozil – – 29.0 62.7 74.7 81.6 84.1 86.8 92.7 98.4b –
Cefpodoxime 54.2 70.1 76.2 81.2 84.4 87.3 96.5 99.6 100.0b – –
Cefotaximec 63.8 72.8 79.1 84.3 89.5 98.3 99.6 99.9 > 99.9b – –
Cefepime – 72.5 77.9 82.8 87.1 97.5 99.7 99.8 > 99.9b – –
Erythromycin – – – 87.1 88.1 89.5 91.2 93.1 95.0 96.2 96.4b
Azithromycin – – 86.1 87.0 88.5 89.4 91.1 92.3 93.8 94.7b –
Clarithromycin – – – 87.5 89.3 90.4 92.3 94.1 95.2 95.4 95.6b
Clindamycin – – – 94.5 94.6 94.7 96.0 100.0 100.0b – –
Gatifloxacin 0.5 0.9 8.2 78.0 99.4 99.7 99.8 99.8b – –
Levofloxacin – – – – 30.7 94.2 99.8 99.8b – – –
Chloramphenicol – – – – – – 71.0 95.6 96.8 99.3b –
Tetracycline – – – – – – 79.5 81.0 82.8 89.1b –
Trimethoprim +
sulphamethoxazole
– – – – 60.5 65.9 – – – – –
Quinupristin + dalfopristin – – – 34.9 95.5 100.0 – – – – –
Vancomycin – – 4.5 53.9 98.9 100.0 – – – – –
aInterpreted by criteria for non-meningitis isolates [9]. The values in bold represent the percentages of susceptible
strains.
bPercentage inhibited at the highest dilution tested.
cPercentage of susceptibility defined by cefuroxime axetil (oral) [9].
dAlso indicates susceptibility spectrum of ceftriaxone [9].
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Fig. 1. Rates of resistance of Streptococcus pneumoniae to
penicillin and erythromycin according to country. Penicil-
lin resistance (a) was divided into intermediate resistance
(MIC of 0.12–1 mg ⁄L) and high-level resistance
(MIC ‡ 2 mg ⁄L), while erythromycin resistance (b) was
divided into mef phenotype (resistance to erythromycin
and susceptibility to clindamycin) and erm phenotype
(resistance to both erythromycin and clindamycin).
Castanheira et al. Antimicrobial susceptibility of Streptococcus pneumoniae 647
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 645–651
equivalent antibacterial activity against all
isolates, with MIC90s of 2, 2 and 1 mg ⁄L, respect-
ively, and resistance rates of 12.9%, 11.5% and
12.5%.
Penicillin resistance rates (MIC ‡ 2 mg ⁄L) var-
ied from 2.8% in Venezuela to 25.0% in Mexico
(Fig. 1a). Comparison of the penicillin resistance
rates among Latin American countries revealed
some remarkable differences. Most penicillin-
non-susceptible isolates from Venezuela and
Brazil showed low-level resistance, whereas
penicillin-non-susceptible isolates from Argentina
and Chile were distributed almost equally in the
intermediate and the highly-resistant categories
(Fig. 1a). Uruguay (1997 only) and Mexico
showed the highest rates of non-susceptible iso-
lates.
The distribution of macrolide resistance rates
according to country is shown in Fig. 1b and was
similar to that of penicillin resistance, except for
Uruguay and Venezuela. However, it is important
to note that some countries did not participate for
the entire 5-year period and only contributed a
small number of isolates. Argentina, Brazil and
Chile contributed 86.9% of the isolates, while
Colombia, Mexico, Uruguay and Venezuela
together contributed only 13.1% of the isolates.
Thus, the results from these countries should be
analysed with caution.
Rates of resistance to penicillin (MIC ‡ 2 mg ⁄L)
and erythromycin (MIC ‡ 1 mg ⁄L) were very
similar throughout the years (Fig. 2). The lowest
penicillin resistance rate was 9.5% in 1997, while
the highest was 13.5% in 1999 (p 0.339).
The in-vitro activity of antimicrobial agents was
also evaluated according to the penicillin suscep-
tibility category of the isolates (Table 2). Against
penicillin-susceptible S. pneumoniae isolates, all
b-lactam compounds demonstrated excellent in-
vitro activity, and susceptibility rates were very
high, except for cefaclor (89.6% susceptibility). As
expected, rates of susceptibility to other b-lactam
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Fig. 2. Penicillin and erythromycin resistance rates accord-
ing to the year of isolation.
Table 2. In-vitro antimicrobial sus-
ceptibilities of penicillin-susceptible,
-intermediate and -resistant Strepto-
coccus pneumoniae isolates according
to their susceptibility to penicillin
Antimicrobial agent
Category (no. of isolates)
Penicillin-susceptible
(1082)
Penicillin-intermediate
(293)
Penicillin-resistant
(186)
MIC50/90
%
Susceptiblea MIC50/90
%
Susceptiblea MIC50/90
%
Susceptiblea
Cefaclor 1 ⁄ 2 89.6 2 ⁄ 32 45.2 > 32 ⁄> 32 0.0
Cefuroximeb £ 0.06 ⁄ 0.12 99.1 0.5 ⁄ 2 67.1 8 ⁄ 8 0.8
Cefprozil 0.25 ⁄ 0.5 99.7 1 ⁄ 8 77.6 16 ⁄ 16 0.0
Cefpodoxime £ 0.03 ⁄ 0.06 99.7 0.25 ⁄ 1 80.0 2 ⁄ 4 0.8
Cefotaximec 0.015 ⁄ 0.03 99.8 0.12 ⁄ 0.5 99.0 1 ⁄ 2 87.5
Cefepime £ 0.06 ⁄ 0.12 99.9 0.12 ⁄ 0.5 99.3 1 ⁄ 2 80.5
Amoxycillin £ 0.06 ⁄ £ 0.06 100.0 0.12 ⁄ 1 100.0 2 ⁄ 4 83.8
Erythromycin 0.25 ⁄ 0.25 92.1 0.5 ⁄ 8 80.6 0.25 ⁄ 8 68.1
Azithromycin £ 0.12 ⁄ £ 0.12 93.0 £ 0.12 ⁄> 16 82.9 £ 0.12 ⁄> 16 71.5
Clarithromycin £ 0.25 ⁄ £ 0.25 92.6 £ 0.25 ⁄ 4 81.3 £ 0.25 ⁄ 16 67.9
Clindamycin £ 0.06 ⁄ 0.25 96.6 £ 0.06 ⁄ 1 89.1 0.12 ⁄ 2 88.6
Gatifloxacin 0.25 ⁄ 0.5 > 99.9 0.25 ⁄ 0.5 100.0 0.25 ⁄ 0.5 98.9
Levofloxacin 1 ⁄ 1 > 99.9 1 ⁄ 1 100.0 1 ⁄ 1 98.9
Chloramphenicol £ 2 ⁄ 4 98.0 £ 2 ⁄ 4 94.2 4 ⁄ 16 83.8
Tetracycline £ 2 ⁄ 16 80.2 £ 2 ⁄> 16 75.9 £ 2 ⁄> 16 81.1
Linezolid 1 ⁄ 1 100.0 1 ⁄ 1 100.0 1 ⁄ 2 100.0
Trimethoprim +
sulphamethoxazole
0.5 ⁄> 1 74.2 > 1 ⁄> 1 44.8 > 1 ⁄> 1 5.5
Quinupristin +
dalfopristin
0.5 ⁄ 0.5 100.0 0.5 ⁄ 1 100.0 0.5 ⁄ 0.5 100.0
Vancomycin 0.25 ⁄ 0.5 100.0 0.5 ⁄ 0.5 100.0 0.5 ⁄ 0.5 100.0
aInterpreted by criteria for non-meningitis isolates [9].
bPercentage of susceptibility defined by cefuroxime axetil (oral) [9].
cAlso indicates susceptibility spectrum of ceftriaxone [9].
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agents were relatively low (0–87.5%) among
penicillin-resistant isolates. Trimethoprim + sul-
phamethoxazole showed the lowest susceptibility
rates (60.5%), which varied from 74.2% among
penicillin-susceptible strains to 5.5% among
strains highly resistant to penicillin (Tables 1
and 2). Linezolid, vancomycin and quinupris-
tin + dalfopristin were the most active com-
pounds overall (100% susceptibility), followed
by the fluoroquinolones gatifloxacin and levofl-
oxacin with 99.8% susceptibility (Tables 1 and 3).
Resistance rates for non-b-lactam drugs were
also higher among penicillin-resistant strains than
among penicillin-susceptible strains. As shown in
Table 2, resistance to fluoroquinolones was not
affected by the susceptibility to penicillin. Chlo-
ramphenicol resistance was more frequent among
isolates highly resistant to penicillin (16.2%) than
among strains with low-level resistance (2.0%).
This correlation with penicillin resistance categ-
ories was not observed for tetracycline, where
around 20% of isolates were resistant regardless
of their penicillin susceptibility category.
Comparison of the susceptibility rates among
countries showed striking differences (Table 3).
Higher rates of resistance were observed in
Mexico compared to Argentina, Brazil and Chile.
In addition, the Brazilian centres showed
trimethoprim + sulphamethoxazole susceptibility
rates (49.7%) that were significantly lower than
those of either the Argentinean or Chilean centres
(49.7% vs. 70.6% and 62.0%, respectively;
p < 0.001).
Twenty-three erythromycin-resistant strains
were screened by molecular methods for ermB
and mefA genes. Ten (43.5%) strains were positive
for ermB and 13 (56.5%) strains were positive for
mefA.
D I S C U S S I O N
An increasing prevalence of penicillin-resistant
pneumococci has been identified throughout the
world. In Latin America, the prevalence of
penicillin resistance among clinical isolates of
pneumococci has also been evaluated by the
Sistema Regional de Vacunas Project [11]. This
programme was conducted by the Pan-American
Health Organization and, similar to the findings
of the present study, its results have shown that
penicillin resistance rates varied markedly
according to country.
Although recent reports from Latin America
[1,2,12] have demonstrated an increase in penicil-
lin resistance rates, the results of the present
study showed stable rates of penicillin suscepti-
bility throughout the period evaluated. High rates
of resistance to other b-lactam agents were expec-
ted in penicillin-non-susceptible strains, since it is
well-documented that the mechanism of resist-
Table 3. In-vitro antimicrobial susceptibility of isolates collected in medical centres participating in the SENTRY
Antimicrobial Surveillance Program (1997–2001)a
Antimicrobial agent
Argentina
(n = 326)
Brazil
(n = 497)
Chile
(n = 533)
Latin America total (n = 1561)
MIC50 ⁄ 90 % Susceptible
b MIC50 ⁄ 90 % Susceptible
b MIC50 ⁄ 90 % Susceptible
b MIC50 ⁄ 90 % Susceptible
b
Cefaclor 1 ⁄> 32 61.6 1 ⁄ 2 79.7 1 ⁄> 32 64.4 1 ⁄> 32 68.2
Cefuroximec £ 0.06 ⁄ 4 86.5 £ 0.06 ⁄ 0.5 93.5 £ 0.06 ⁄ 8 76.8 £ 0.06 ⁄ 4 81.3
Cefprozil 0.25 ⁄ 8 85.7 0.25 ⁄ 1 93.1 0.25 ⁄ 16 77.4 0.25 ⁄ 8 84.1
Cefpodoxime £ 0.03 ⁄ 1 86.9 £ 0.03 ⁄ 0.25 93.8 0.06 ⁄ 2 76.5 £ 0.03 ⁄ 2 84.4
Cefotaximed 0.03 ⁄ 0.25 98.2 0.03 ⁄ 0.12 98.6 0.03 ⁄ 1 98.2 0.03 ⁄ 1 98.3
Cefepime £ 0.06 ⁄ 1 97.5 £ 0.06 ⁄ 0.25 99.2 0.12 ⁄ 1 97.0 £ 0.06 ⁄ 1 97.5
Amoxycillin £ 0.06 ⁄ 1 100.0 £ 0.06 ⁄ 0.12 98.8 £ 0.06 ⁄ 2 97.8 £ 0.06 ⁄ 1 98.2
Erythromycin 0.25 ⁄ 1 86.5 0.25 ⁄ 1 88.5 0.25 ⁄ 4 88.0 0.25 ⁄ 2 87.1
Azithromycin £ 0.12 ⁄ 0.5 90.0 £ 0.12 ⁄ 0.5 91.4 £ 0.12 ⁄ 2 86.7 £ 0.12 ⁄ 2 88.5
Clarithromycin £ 0.25 ⁄ 0.5 88.1 £ 0.25 ⁄ 0.5 89.2 £ 0.25 ⁄ 2 87.2 £ 0.25 ⁄ 1 87.5
Clindamycin £ 0.06 ⁄ 0.25 93.3 0.12 ⁄ 0.25 94.6 £ 0.06 ⁄ 0.25 96.6 £ 0.06 ⁄ 0.25 94.5
Gatifloxacin 0.25 ⁄ 0.5 99.4 0.25 ⁄ 0.5 100.0 0.25 ⁄ 0.5 99.6 0.25 ⁄ 0.5 99.8
Levofloxacin 1 ⁄ 1 99.6 1 ⁄ 1 100.0 1 ⁄ 1 99.6 1 ⁄ 1 99.8
Chloramphenicol £ 2 ⁄ 4 93.3 £ 2 ⁄ 4 98.2 £ 2 ⁄ 4 97.6 £ 2 ⁄ 4 95.6
Tetracycline £ 2 ⁄> 16 82.2e £ 2 ⁄> 16 80.5e £ 2 ⁄> 16 84.4e £ 2 ⁄> 16 81.0e
Linezolid 1 ⁄ 1 100.0 1 ⁄ 1 100.0 1 ⁄ 2 100.0 1 ⁄ 1 100.0
Trimethoprim + sulphamethoxazole £ 0.5 ⁄> 1 70.6 0.5 ⁄> 1 49.7 £ 0.5 ⁄> 1 62.0 0.5 ⁄> 1 60.5
Quinupristin + dalfopristin 0.5 ⁄ 0.5 100.0 0.5 ⁄ 0.5 100.0 0.5 ⁄ 0.5 100.0 0.5 ⁄ 0.5 100.0
Vancomycin 0.25 ⁄ 0.5 100.0 0.25 ⁄ 0.5 100.0 0.25 ⁄ 0.5 100.0 0.25 ⁄ 0.5 100.0
aOnly countries with more than 300 isolates are included individually in the table.
bInterpreted according to criteria for non-menigitis isolates [9].
cPercentage of susceptibility defined by cefuroxime axetil (oral) [9].
dAlso indicates susceptibility spectrum of ceftriaxone [9].
eIncludes susceptible and intermediate isolates.
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ance to b-lactam agents is altered penicillin-
binding proteins [13]. The difference between
pneumococci susceptibility rates for penicillin
and amoxycillin is explained by differences in
the susceptibility breakpoints (£ 0.06 mg ⁄L for
penicillin and £ 2 mg ⁄L for amoxycillin), since
both b-lactam compounds have similar activity
in vitro against this pathogen [9].
Cefotaxime resistance was found in 0.4% of
isolates; however, only two isolates were from
blood, while the others were isolated from the
respiratory tract. These strains were isolated from
different Latin American countries during 1997–
1999. Strains highly resistant to penicillin showed
a tendency to be more resistant to some antimi-
crobial agents, including non-b-lactam com-
pounds. The reasons for cross-resistance to
several antimicrobial classes are not completely
understood, but some resistant determinants are
carried on the same mobile genetic elements [2].
Despite the mechanisms of resistance to
macrolides being completely distinct from those
causing b-lactam resistance, penicillin-non-sus-
ceptible S. pneumoniae isolates are usually less
susceptible to this agent [1]. Macrolide resistance
in S. pneumoniae may be caused by two distinct
mechanisms of resistance: (1) target-site modifi-
cation by methylation of the 23S ribosomal RNA;
and (2) efflux of the antibiotic, associated with
expression of the mefE gene. Ribosomal methy-
lation, encoded by the erm gene, leads to
cross-resistance to macrolides, lincosamides
(clindamycin) and streptogramin B, the so-called
MLSB phenotype. The efflux mechanism is
caused by an inducible expressed pump that
confers resistance only to macrolides. Based on
the clindamycin results, 42.5% of erythromycin-
resistant strains appeared to carry the MLSB
phenotype, while 57.5% seemed to possess the
efflux mechanism. The molecular analysis per-
formed on the isolates collected in 2001 con-
firmed these results, since 43.5% of isolates were
positive for ermB and 56.5% were positive for
mefA. On the other hand, these results are in
contrast to those obtained by the Sistema
Regional de Vacunas Project, which showed that
MLSB was the most common macrolide resist-
ance phenotype [12].
Other investigators [1,12,14,15] have also repor-
ted elevated rates of resistance to tetracycline and
trimethoprim + sulphamethoxazole in Latin
American countries. The low cost and easy access
to these drugs recommended by the World Health
Organisation may, in part, explain these higher
rates of resistance. On the other hand, chloram-
phenicol showed an excellent spectrum against
Latin American pneumococcal isolates (95.6%
susceptibility overall).
Fluoroquinolones with enhanced anti-pneumo-
coccal activity (e.g., gatifloxacin and levofloxacin)
represent attractive antimicrobial treatment op-
tions for community-acquired respiratory infec-
tions in adults [16,17]. Currently, resistance to
these fluoroquinolones (gatifloxacin and levofl-
oxacin) is very rare in Latin American isolates
(< 1%) [1,14,15]. The present study found three
isolates (0.19%) resistant to both gatifloxacin and
levofloxacin. These strains were from Chile (two
isolates) and Argentina (one isolate), and all three
had a double mutation in the quinolone resist-
ance-determining region. Resistance to vancomy-
cin, linezolid and quinupristin + dalfopristin was
not observed. These drugs and the fluoroquino-
lones were the most active compounds against
penicillin-resistant S. pneumoniae.
Several surveillance programmes have evalu-
ated the antimicrobial susceptibility of S. pneumo-
niae in the last few years. However, the number of
isolates from the Latin America region is usually
low. The present study tested a large number of
isolates against most antimicrobial agents cur-
rently used to treat pneumococcal infections. The
results highlighted the main resistance problems
and showed that resistance rates may vary signi-
ficantly among regions and also within a geo-
graphical region. It is important to note that the
study collected isolates from a limited number of
centres in a very large and diverse geographical
area. Thus, the results may not reflect the resist-
ance rates in other countries of the region, or in
other regions of the countries evaluated.
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